Test Price
2,800 AED✅ Home Collection Available
AML Prognostic Panel (Cytogenetics + PCR) in UAE | 2,800 AED
Executive Summary & Core Metrics
- Diagnostic Precision: 99.9% sensitivity via ISO 15189 accredited cytogenetic and molecular processing.
- Logistical Protocol: Hospital Extraction Only – Sample collection is conducted strictly within an accredited hospital facility; mobile home phlebotomy is disabled for safety.
- Clinical Guidance: Post-result telephonic interpretation and management consultation included.
- Insurance & Billing: Direct billing verification and insurance pre-approval support via WhatsApp +971 54 548 8731.
- Regulatory Anchor: Full compliance with UAE PDPL and DHA/MOHAP diagnostic standards.
Test Overview & Methodology
The AML Prognostic Panel is a comprehensive genomic risk-stratification assay for acute myeloid leukemia (AML). It integrates conventional karyotyping (chromosome banding analysis) with targeted end-point polymerase chain reaction (PCR) to detect both structural chromosomal rearrangements and clinically actionable gene mutations. The panel identifies core-binding factor fusions (AML1-ETO, INV(16)), the acute promyelocytic leukemia driver (PML-RARA), and critical molecular markers (FLT3-ITD/TKD, NPM1, CEBPA) essential for European LeukemiaNet (ELN) risk categorization.
| Feature | DNA Labs UAE – Integrated Panel | Standard Disjointed Workflow |
|---|---|---|
| Analytical Scope | Simultaneous structural (karyotype) & molecular (PCR) aberrations | Sequential send-out cytogenetics + separate PCR delays |
| Turnaround Time | 5–7 working days | 10–14 working days |
| Cold-Chain Integrity | ISO-certified continuous temperature monitoring (2–8 °C) | Variable transport conditions; elevated degradation risk |
| Clinical Actionability | Single report with ELN risk class, targeted therapy options, clinical trial eligibility flags | Fragmented reports requiring manual integration by hematologist |
Interpretation requires multidisciplinary collaboration among hematopathologists, molecular geneticists, and clinical oncology teams.
Physician Insight & Safety Protocols
“As the Specialist Diagnostic Radiology overseeing advanced diagnostic integration at DNA Labs UAE, I emphasize that precise AML subclassification is the cornerstone of modern targeted therapy. This panel provides the complete genomic landscape necessary for accurate ELN risk stratification. Patients and referring physicians must review the full report in the context of morphology, immunophenotyping, and clinical presentation. No therapeutic decision should be made solely on a single molecular result.” – Mr. Prabhakar Reddy Kalathoor, Specialist Diagnostic Radiology | DHA Registration ID: 61713011
Critical Advisory: Medication & Therapy Continuation
Do not discontinue, adjust, or initiate any prescribed chemotherapy, targeted agent, or supportive medication without explicit instruction from your treating hematologist. This prognostic panel is designed to inform clinical decision-making and should not replace professional medical judgment.
Clinical Exclusion Criteria & Emergency Red Flags
- Exclusion Criteria: Patients with acute symptomatic anemia requiring immediate packed red cell transfusion, active untreated bleeding diathesis, or inability to tolerate the bone marrow aspiration procedure. Pediatric patients must be managed under the direct supervision of a qualified pediatric hematologist-oncologist.
- Emergency Indicators: Seek immediate emergency care if you experience uncontrolled hemorrhage, persistent fever exceeding 38.5 °C, severe localized pain or swelling at the aspiration site, or any signs of systemic infection.
- Logistical Confirmation: Hospital Extraction Only – This invasive procedure is conducted exclusively within accredited hospital facilities under sterile conditions. Mobile phlebotomy is not clinically appropriate for bone marrow acquisition.
Patient FAQ & Clinical Guidance
1. What specific genetic mutations and rearrangements does this panel detect?
The panel detects the complete repertoire of ELN-recommended markers: fusion genes AML1-ETO (RUNX1-RUNX1T1), CBFB-MYH11 (INV(16)), PML-RARA; and gene mutations in FLT3 (ITD and TKD), NPM1, and biallelic CEBPA. This combination covers favorable, intermediate, and adverse risk categories per the 2022 ELN guidelines.
2. Why is a bone marrow aspirate preferred over a peripheral blood sample for this test?
Bone marrow aspirate provides a higher blast cell concentration, ensuring optimal metaphase yield for karyotyping and maximal nucleic acid purity for PCR amplification. Peripheral blood may be used as an alternative only when marrow aspiration is clinically contraindicated, but it carries a higher risk of false-negative cytogenetic results due to lower blast counts.
3. How are results delivered, and is post-test counseling available?
A secure PDF report is made available electronically within 5–7 working days, containing the integrated karyotype and molecular findings, ELN risk classification, and clinically actionable recommendations. DNA Labs UAE offers a complimentary telephonic consultation with a qualified specialist to walk patients and referring physicians through the implications of the results and to coordinate further management steps.
UAE Regulatory & Data Privacy Adherence
DNA Labs UAE strictly adheres to the following legislative and regulatory frameworks:
- Data Protection: Full compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) for all patient health information processing, storage, and sharing.
- Health Information Technology: Conformity with Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields, ensuring secure digital diagnostic record management.
- Medical Liability & Consent: Adherence to Federal Decree-Law No. 4 of 2016 on Medical Liability, guaranteeing that all invasive procedures (bone marrow aspiration) are performed with explicit informed consent and under strict clinical safety standards.
- Accreditation: ISO 9001:2015 certified (Cert: INT/EGQ/2509DA/3139), following DHA and MOHAP regulatory guidelines for diagnostic laboratory practice.
Clinical & Logistical Metadata
| Test Name | AML Prognostic Panel (Cytogenetics + PCR) |
| Price (AED) | 2,800 AED |
| Turnaround Time | 5–7 Working Days |
| Sample Type / Matrix | Bone Marrow Aspirate (preferred) / Peripheral Blood (alternative) |
| Methodology Used | Integrated Chromosome G-Banding (Karyotyping) & End-Point PCR (FLT3, NPM1, CEBPA) |
| ICD-10-CM Code | C92.0 (Acute myeloblastic leukemia) |
| LOINC Code | 88277-7 (Acute myeloid leukemia panel) |
| DHA Facility License & Address | License No: 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians